GB/Z 16886.22-2022
ActiveBiological evaluation of medical devices—Part 22:Guidance on nanomaterials
医疗器械生物学评价 第22部分：纳米材料指南
Application Summary AI generated
This standard provides guidance on evaluating the biological safety of medical devices that incorporate or release nanomaterials. It is applied by manufacturers and testing laboratories during the risk assessment and biocompatibility testing of products such as nanocoated implants, drug-delivery systems, or wound dressings containing nanoparticles. The guidance addresses specific challenges like nanoparticle characterization, toxicokinetics, and immune response, ensuring compliance with regulatory requirements in the healthcare industry.
Related Standards
GB/T 19634-2005
In vitro diagnostic test systems-General technical requirements for blood-glucose monitoring systems for self-testing
GB/T 47486-2026
General technical requirements for vasculature-on-a-chip
GB/Z 30154-2013
Medical laboratories―Guidance on laboratory implementation of GB/T 22576-2008
GB/Z 43280-2023
Medical laboratories—Practical guidance for the estimation of measurement uncertainty
GB/Z 43281-2023
Guidance for supervisors and operators of point-of-care testing(POCT) devices
GB/Z 44363-2024
Pyrogenicity—Principles and methods for pyrogen testing of medical devices
GB/Z 136-2026
Medical laboratories—Reagents for staining biological specimen—Guidance for users
GB/Z 157-2026
In vitro diagnostic test systems—Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods
Transparency note: The application summary and key sentences on this page were automatically generated by AI from the standard's original text. This content has not been human-verified and should not be used for compliance or regulatory purposes. Always refer to the official standard document from the issuing authority.